ALSO IN EARNINGS
- Facebook Fiasco: 10 Things Underwriters Got Wrong
- Sticker Shock: What College Is Likely to Cost in 18 Years
- Marc Faber: 100% Chance of Global Recession
- Citigroup Lost $20 Million on Facebook IPO Trades
- Main Players in the Greek Election
- Many Greeks Moved Their Money Abroad Long Ago
- Bankia Asks Spain for $24 Billion Bailout
- European Consumers 'Hit With a One-Two Punch': Kilduff
- Still Like Facebook? There’s an ETF for That.
MOST SHARED
- Citigroup Lost $20 Million on Facebook IPO Trades
- Many Greeks Moved Their Money Abroad Long Ago
- S&P Cuts Ratings on Five Spanish Banks
- Are Investors Running Out of Safe Havens to Put Money?
- Reum: Successfully Marketing Liquor through Facebook
- CNBC Webinar: Competitive-Edge Technologies for Advanced Manufacturing
- Europe Fights Argentina's 'Protectionist' Import Rules
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Kansas City Fed President Steps Into Jamie Dimon Debate
- Facebook IPO Fiasco: 10 Things Underwriters Got Wrong
MOST POPULAR
HOT ON FACEBOOK
Merck's Profit Jumps 62%; Drug Maker Raises Outlook
Text Size 
Merck Monday reported a better-than-expected profit, helped by sales of its vaccines and cholesterol drugs, and raised its 2007 profit forecast in view of strong current trends.
 |
"Our third-quarter results reflect the continued progress Merck is making to deliver on our strategy," chief executive officer Richard Clarke said in a statement.
The company said it earned $1.53 billion, or 70 cents per share, compared with $941 million, or 43 cents per share, in the year-ago period when it took $598 million charge for legal expenses related to its withdrawn Vioxx arthritis drug.
Excluding restructuring charges, Merck [MRK
Loading...
()
] earned 75 cents per share, ahead of the 69 cents per share expected on average by analysts, according to Reuters Estimates.
Sales of the cholesterol drugs Zetia and Vytorin, which the company sells in a joint venture with Schering-Plough [SGP
Loading...
()
] , rose 26 percent to $1.3 billion.
Schering-Plough said on Monday its third-quarter earnings more than doubled, powered by higher sales of the cholesterol drugs and non-operating items, but profit and sales came in below Wall Street's target.
Merck's vaccine sales more than doubled to $1.2 billion.
Gardasil, Merck's cervical cancer vaccine, posted sales of $418 million.
Sales of allergy and asthma treatment Singulair rose 17 percent to $1 billion.
Merck projected 2007 earnings per share of $3.08 to $3.14, excluding the restructuring charges related to site closures and position eliminations. It previously forecast $3 to $3.10 per share.
Merck shares rose 19 cents to $53.30 in early electronic trading from a Friday close of $53.11 on the New York Stock Exchange.
- The Nasdaq has suffered the most from the EU crisis showing there's risk in the usual tech stocks.
- Targeting more Millennials is just one of the items brewing for consumers in the world of spirits.
- It seems many people may need a reminder of how NOT to act on a plane. Here are a few tips.
- Here are some very unusual roadside stops along American highways that might peek your interest.
- How three generations of Americans are dealing with the finances of retirement.
Data is a real-time snapshot *Data is delayed at least 15 minutes
